Regeneron Pharmaceuticals, Inc. (REGN)

US — Healthcare Sector
Peers: VRTX  BMRN  SRPT  ALNY  BIIB  GILD  ILMN 

Automate Your Wheel Strategy on REGN

With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol REGN
  • Rev/Share 135.2445
  • Book/Share 284.8611
  • PB 1.9738
  • Debt/Equity 0.0904
  • CurrentRatio 4.5976
  • ROIC 0.1047

 

  • MktCap 58571832332.0
  • FreeCF/Share 36.5804
  • PFCF 15.2348
  • PE 13.2541
  • Debt/Assets 0.0708
  • DivYield 0.0047
  • ROE 0.1511

 

  • Rating A
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 5
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation REGN Rothschild & Co Redburn -- Buy -- $890 Aug. 14, 2025
Downgrade REGN Argus Buy Hold -- -- June 30, 2025
Downgrade REGN Wells Fargo Overweight Equal Weight -- $580 May 30, 2025
Downgrade REGN RBC Capital Mkts Outperform Sector Perform -- $662 May 30, 2025
Upgrade REGN Citigroup Neutral Buy -- $700 May 14, 2025
Resumed REGN Cantor Fitzgerald -- Overweight -- $695 April 22, 2025
Upgrade REGN Leerink Partners Market Perform Outperform $762 $834 Feb. 5, 2025
Downgrade REGN UBS Buy Neutral $1130 $738 Jan. 16, 2025
Resumed REGN BofA Securities -- Underperform -- $565 Dec. 10, 2024
Downgrade REGN Leerink Partners Outperform Market Perform $1175 $1077 Sept. 24, 2024

News

Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin
APH, LMT, NVDA, REGN
Published: September 30, 2025 by: CNBC Television
Sentiment: Neutral

CNBC's "Halftime Report" team detail their stock picks and final trades.

Read More
image for news Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
REGN
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.

Read More
image for news FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
REGN
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.

Read More
image for news Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
REGN, SNY
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive

Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.

Read More
image for news SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
REGN
Published: September 19, 2025 by: Reuters
Sentiment: Positive

Regeneron said on Friday its experimental therapy showed either a complete or partial disappearance of a precancerous disorder, which manifests into blood cancer, in all patients in a mid-stage trial.

Read More
image for news Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
Regeneron's bone disorder treatment succeeds in late-stage trial
REGN
Published: September 17, 2025 by: Reuters
Sentiment: Positive

Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder that affects bone tissue has met the main goal of a late-stage trial.

Read More
image for news Regeneron's bone disorder treatment succeeds in late-stage trial
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
REGN
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation

Read More
image for news Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
REGN
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Negative

Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.

Read More
image for news REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
REGN
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Christopher Fenimore - Executive VP of Finance & CFO Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman Marion McCourt - Executive Vice President of Commercial Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.

Read More
image for news Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
REGN
Published: September 08, 2025 by: Benzinga
Sentiment: Positive

Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary endpoints.

Read More
image for news What's Happening With Regeneron Pharmaceuticals Stock On Monday?
A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
JNJ, REGN
Published: August 21, 2025 by: CNBC
Sentiment: Positive

Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is five years and $3.2 billion in the making.

Read More
image for news A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
FDA Extends Review Period of REGN's Submission for Eylea HD
REGN
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Neutral

The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.

Read More
image for news FDA Extends Review Period of REGN's Submission for Eylea HD
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
REGN
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications.

Read More
image for news EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
REGN
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive

REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Read More
image for news Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity
REGN
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive

Regeneron's Q2 showed strong earnings and cash flow, driven by DUPIXENT's growth and operational discipline, despite EYLEA's ongoing revenue decline. EYLEA faces intense competition and margin pressure, but DUPIXENT's expanding indications and LIBTAYO's solid performance offset these headwinds. Regeneron's oncology pipeline is advancing, highlighted by LYNOZYFIC's approval, while strategic moves in obesity drugs aim for future growth.

Read More
image for news Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
REGN
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO George D.

Read More
image for news Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
Nonfarm Payrolls Come in SIgnificantly Below Expectations
CL, CVX, REGN, XOM
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Negative

Nonfarm Payrolls Come in SIgnificantly Below Expectations.

Read More
image for news Nonfarm Payrolls Come in SIgnificantly Below Expectations
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
REGN
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive

REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.

Read More
image for news Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
REGN
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
REGN
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Read More
image for news Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
5 Stocks That Launched New Dividends In This Roller-Coaster Market
MRP, REGN, VTOL, WDC, WSC
Published: July 29, 2025 by: Forbes
Sentiment: Positive

Brand new dividends are often the best divvies to buy. Here why.

Read More
image for news 5 Stocks That Launched New Dividends In This Roller-Coaster Market
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
REGN
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
REGN
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.

Read More
image for news REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
REGN
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Negative

Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

Read More
image for news Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
REGN
Published: July 10, 2025 by: Seeking Alpha
Sentiment: Positive

Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Regeneron's key "cash cow" and its savior, the profit from sales of which will rise sharply in 2027. From its oncology franchise, I highlight Lynozyfic, which received its first FDA approval on July 2, and Libtayo, whose sales reached $285 million in Q1 2025.

Read More
image for news Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
REGN
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

Read More
image for news FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
REGN
Published: July 02, 2025 by: WSJ
Sentiment: Positive

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

Read More
image for news Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
US FDA approves Regeneron's blood cancer therapy
REGN
Published: July 02, 2025 by: Reuters
Sentiment: Positive

The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.

Read More
image for news US FDA approves Regeneron's blood cancer therapy
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
REGN, UTHR
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
REGN
Published: June 25, 2025 by: Seeking Alpha
Sentiment: Positive

Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robust near-term revenue driver. Libtayo and the oncology pipeline offer potential, but face tough competition and are unlikely to become blockbuster catalysts in the short term. The company's move into obesity drugs is a favorable development, with considerable potential from its experimental drug Trevogrumab, which shows promise in early trial data.

Read More
image for news Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade

About Regeneron Pharmaceuticals, Inc. (REGN)

  • IPO Date 1991-04-02
  • Website https://www.regeneron.com
  • Industry Biotechnology
  • CEO Leonard S. Schleifer
  • Employees 15158

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.